Incidence, prevalence, and real-world treatment patterns in chronic myeloid leukemia: results from a population-representative German claims data analysis
Introduction: Real-world data on usage of 1st-, 2nd-, and 3rd-generation tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) are scarce. This study therefore aimed to analyze the use of different TKIs used in 1st- and 2nd-line treatment and the frequency of TKI switches in CML. Methods...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 2022
|
| In: |
Oncology research and treatment
Year: 2022, Jahrgang: 45, Heft: 7-8, Pages: 400-406 |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000524284 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000524284 Verlag, lizenzpflichtig, Volltext: https://karger.com/ort/article/45/7-8/400/826105/Incidence-Prevalence-and-Real-World-Treatment 
|
| Verfasserangaben: | Susanne Saußele, Katharina Kohlbrenner, Tobias Vogelmann, Tino Schubert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1896052967 | ||
| 003 | DE-627 | ||
| 005 | 20241205153804.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240723s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000524284 |2 doi | |
| 035 | |a (DE-627)1896052967 | ||
| 035 | |a (DE-599)KXP1896052967 | ||
| 035 | |a (OCoLC)1475303926 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Saußele, Susanne |d 1968- |e VerfasserIn |0 (DE-588)115839860 |0 (DE-627)69162786X |0 (DE-576)29010694X |4 aut | |
| 245 | 1 | 0 | |a Incidence, prevalence, and real-world treatment patterns in chronic myeloid leukemia |b results from a population-representative German claims data analysis |c Susanne Saußele, Katharina Kohlbrenner, Tobias Vogelmann, Tino Schubert |
| 264 | 1 | |c August 2022 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 25. März 2022 | ||
| 500 | |a Gesehen am 23.07.2024 | ||
| 520 | |a Introduction: Real-world data on usage of 1st-, 2nd-, and 3rd-generation tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) are scarce. This study therefore aimed to analyze the use of different TKIs used in 1st- and 2nd-line treatment and the frequency of TKI switches in CML. Methods: This observational study was based on the InGef research database, an anonymized representative claims dataset in Germany (n = 4 million). An incidence and prevalence patient CML cohort was followed for 5 and 3 years. Analyses regarding incidence, prevalence, and therapy distribution were performed descriptively. Results: 151 patients were included in the incidence and 636 patients in the prevalence cohort. This resulted in an incidence of 1.8 (95% confidence interval [CI]: 1.34-2.20) and a prevalence of 14.9 (95% CI: 13.70-16.03) per 100,000 inhabitants. For the incidence cohort, data on 1st-line therapy were available for 124 patients and distributed across imatinib (N = 52), nilotinib (N = 44), dasatinib (N = 12), chemotherapies as hydroxycarbamide (N = 11), and ponatinib/bosutinib (N = 5). Twenty-six percent of patients switched TKI therapy at least once in 3 years. In the prevalence cohort, 423 patients (66.5%) had claims on existing or newly emerged cardiovascular diseases (CDs). No significant differences (p = 0.32) between TKIs in patients with CD were found. Discussion: Every fourth patient switched TKI therapy within the first 3 years after treatment initiation. Switches were more likely when hints of disease progression or intolerability were observable in the database. | ||
| 700 | 1 | |a Kohlbrenner, Katharina |d 1970- |e VerfasserIn |0 (DE-588)128734647 |0 (DE-627)378683772 |0 (DE-576)297304968 |4 aut | |
| 700 | 1 | |a Vogelmann, Tobias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schubert, Tino |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology research and treatment |d Basel : Karger, 2014 |g 45(2022), 7-8 vom: Aug., Seite 400-406 |h Online-Ressource |w (DE-627)776629611 |w (DE-600)2749752-5 |w (DE-576)400081660 |x 2296-5262 |7 nnas |a Incidence, prevalence, and real-world treatment patterns in chronic myeloid leukemia results from a population-representative German claims data analysis |
| 773 | 1 | 8 | |g volume:45 |g year:2022 |g number:7-8 |g month:08 |g pages:400-406 |g extent:7 |a Incidence, prevalence, and real-world treatment patterns in chronic myeloid leukemia results from a population-representative German claims data analysis |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000524284 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://karger.com/ort/article/45/7-8/400/826105/Incidence-Prevalence-and-Real-World-Treatment |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240723 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 128734647 |a Kohlbrenner, Katharina |m 128734647:Kohlbrenner, Katharina |d 60000 |d 61200 |e 60000PK128734647 |e 61200PK128734647 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 998 | |g 115839860 |a Saußele, Susanne |m 115839860:Saußele, Susanne |d 60000 |d 61200 |d 60000 |e 60000PS115839860 |e 61200PS115839860 |e 60000PS115839860 |k 0/60000/ |k 1/60000/61200/ |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1896052967 |e 4555824644 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1896052967"],"doi":["10.1159/000524284"]},"name":{"displayForm":["Susanne Saußele, Katharina Kohlbrenner, Tobias Vogelmann, Tino Schubert"]},"physDesc":[{"extent":"7 S."}],"recId":"1896052967","relHost":[{"origin":[{"publisherPlace":"Basel","dateIssuedDisp":"2014-","dateIssuedKey":"2014","publisher":"Karger"}],"pubHistory":["37.2014 -"],"note":["Gesehen am 15.12.2023"],"title":[{"title_sort":"Oncology research and treatment","title":"Oncology research and treatment"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Incidence, prevalence, and real-world treatment patterns in chronic myeloid leukemia results from a population-representative German claims data analysisOncology research and treatment","physDesc":[{"extent":"Online-Ressource"}],"recId":"776629611","id":{"zdb":["2749752-5"],"issn":["2296-5262"],"eki":["776629611"]},"language":["eng"],"part":{"year":"2022","pages":"400-406","text":"45(2022), 7-8 vom: Aug., Seite 400-406","issue":"7-8","volume":"45","extent":"7"}}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"August 2022","dateIssuedKey":"2022"}],"note":["Online veröffentlicht: 25. März 2022","Gesehen am 23.07.2024"],"title":[{"title_sort":"Incidence, prevalence, and real-world treatment patterns in chronic myeloid leukemia","subtitle":"results from a population-representative German claims data analysis","title":"Incidence, prevalence, and real-world treatment patterns in chronic myeloid leukemia"}],"language":["eng"],"person":[{"family":"Saußele","display":"Saußele, Susanne","role":"aut","given":"Susanne"},{"given":"Katharina","role":"aut","family":"Kohlbrenner","display":"Kohlbrenner, Katharina"},{"role":"aut","given":"Tobias","family":"Vogelmann","display":"Vogelmann, Tobias"},{"role":"aut","given":"Tino","family":"Schubert","display":"Schubert, Tino"}]} | ||
| SRT | |a SAUSSELESUINCIDENCEP2022 | ||